Related Experiment Video

Updated: May 1, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

J J Ko1, T K Choueiri2, B I Rini3

  • 1Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.

British Journal of Cancer
|April 3, 2014
PubMed
Abstract

Insights

Metastatic renal cell carcinoma patients receiving multiple lines of targeted therapy (TT) demonstrate significantly longer overall survival (OS) and progression-free survival (PFS). These survival benchmarks are crucial for clinical trial design and patient counseling in mRCC.

Area of Science:

  • Oncology
  • Clinical Research
  • Biostatistics

Background:

  • Limited data exist on the survival outcomes for metastatic renal cell carcinoma (mRCC) patients undergoing multiple lines of targeted therapy (TT).
  • Establishing survival benchmarks is essential for informed patient counseling and effective clinical trial design in mRCC.
  • Previous studies have not comprehensively analyzed outcomes across varying numbers of TT lines.

Purpose of the Study:

  • To compare the survival outcomes of mRCC patients treated with one, two, or three or more lines of TT.
  • To establish survival benchmarks for mRCC patients receiving sequential TT.
  • To provide data for patient counseling and clinical trial design.

Main Methods:

  • Analysis of data from the International mRCC Database Consortium database.
  • Inclusion of 2705 mRCC patients treated with TT.
  • Comparison of overall survival (OS) and progression-free survival (PFS) using proportional hazards regression, with subgroup analyses based on trial eligibility criteria.

Main Results:

  • Patients receiving 2 lines (21.0 months OS) and 3+ lines (39.2 months OS) of TT showed significantly longer OS compared to those receiving 1 line (14.9 months OS).
  • Multivariable analysis confirmed that 2 lines (HR=0.738) and 3+ lines (HR=0.626) of TT were associated with improved OS.
  • Overall survival for all patients was 20.9 months and PFS was 7.2 months, with variations across subgroups mirroring specific clinical trial populations.

Conclusions:

  • Patients with mRCC who receive multiple lines of TT experience longer survival durations.
  • The established survival benchmarks offer valuable context for interpreting clinical trial results and for designing future mRCC therapeutic strategies.
  • Sequential targeted therapy demonstrates a survival benefit in metastatic renal cell carcinoma.

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.9K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627